Kalydeco Now Approved for Expanded Cystic Fibrosis Treatment
May 18th 2017FDA officials have announced the expanded approval of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to triple the number of rare gene mutations of cystic fibrosis that the drug is indicated to treat, from 10 mutations to 33.
Read More